Risk factor
Poor trading liquidity
Profitability factor
Very strong margins and returns
About
Established in 1984 and headquartered in Ahmedabad, India, Concord Biotech Limited operates as a biopharmaceutical company engaged in the comprehensive research, development, manufacturing, marketing, and global sales of pharmaceutical products. The company primarily specializes in producing fermentation-based active pharmaceutical ingredients (APIs) for a diverse range of critical therapeutic areas, including immunosuppression, anti-bacterial treatments, oncology, and antifungal applications, among others. Its extensive product catalog features immunosuppressants such as tacrolimus and cyclosporine; oncology agents like everolimus and mitomycin; antibacterial compounds including vancomycin hydrochloride; antifungal drugs such as caspofungin; and additional APIs like lovastatin. Furthermore, Concord Biotech extends its expertise to provide contract research and manufacturing services (CRAMS) focused on fermentation and semi-synthesis products.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,
Target Price
The average target price of CONCORDBIO.BO is 1140 and suggests 8.73% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommenda